Wedbush Assumes Achillion Pharmaceuticals (ACHN) at Outperform; Diverse and Differentiated Pipeline
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Price: $0.79 --0%
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Wedbush assumes coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Outperform. PT $11.00.
Wedbush analyst says, "Our thesis centers on the conviction that Achillion holds a diverse and differentiated pipeline of next-generation candidates for treating Hepatitis C...We believe Achillion is well-positioned for lucrative partnership agreements or an outright acquisition...Our Fair Value of $11 per share represents a compelling risk/reward opportunity, in our opinion."
For more ratings news on Achillion Pharmaceuticals click here and for the rating history of Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $7.64 yesterday.
Wedbush analyst says, "Our thesis centers on the conviction that Achillion holds a diverse and differentiated pipeline of next-generation candidates for treating Hepatitis C...We believe Achillion is well-positioned for lucrative partnership agreements or an outright acquisition...Our Fair Value of $11 per share represents a compelling risk/reward opportunity, in our opinion."
For more ratings news on Achillion Pharmaceuticals click here and for the rating history of Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $7.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- TD Cowen Assumes Nektar Therapeutics (NKTR) at Buy
- Keefe, Bruyette & Woods Resumes Royal Bank of Canada (RY:CN) (RY) at Market Perform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
